Ionis Enlists Bicycle To Open Up New Antisense Targets In Bounce-Back Bid

Aiming To Cross Blood Brain Barrier

Small-molecule drug delivery tech could help Ionis deliver its oligonucleotides where others cannot reach.

Ionis HQ — Ionis has three products on the market, but is still loss-making and needs to expand the reach of its RNA-based medicines. • Source: Ionis

Ionis Pharmaceuticals is to work with Bicycle Therapeutics to open up new avenues for its oligonucleotide platform using novel drug delivery technologies to target muscle tissue, the heart and the brain.

The company is paying $45m upfront to Bicycle, as well as development, commercial milestones and royalties, in exchange for access to its

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

19 May 2025

• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

16 May 2025

• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

16 May 2025

• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

16 May 2025

• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.